Zkusit zdarma
Merck & Co., Inc.

Merck & Co., Inc.

MRK
Cena:
$ 122.41
+6.53 (5.64%)
Valuace
15
Růst
38
Zdraví
78
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Merck stock jumps as Keytruda combo trials boost cancer pipeline

Merck stock jumps as Keytruda combo trials boost cancer pipeline

14:31 22-05-2026

Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive devel...

Will Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?

Will Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?

12:15 22-05-2026

Merck's Gardasil sales plunge as weak China demand, inventory issues and softer Japan trends cloud t...

Pharma Stock Pops On European Seal of Approval

Pharma Stock Pops On European Seal of Approval

10:51 22-05-2026

Merck (NYSE:MRK) stock is up 5% to trade at $121.75, after the blue-chip pharma giant received the ...

Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

10:23 22-05-2026

Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytr...

Merck Stock Zooms Closer To A Breakout On 'A New Chapter' In Cancer

Merck Stock Zooms Closer To A Breakout On 'A New Chapter' In Cancer

9:07 22-05-2026

Merck stock popped early Friday after European officials recommended approving its combination for a...

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

7:55 22-05-2026

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Cana...

Kelun, Merck's lung cancer combo improves survival in late-stage China trial

Kelun, Merck's lung cancer combo improves survival in late-stage China trial

17:06 21-05-2026

Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with pa...

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer

8:00 21-05-2026

DARMSTADT, Germany--(BUSINESS WIRE)--Merck Announces First Patient Dosed in Phase 3 Study for Invest...

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda

7:28 18-05-2026

A late-stage trial evaluating Regeneron's fianlimab, a skin cancer drug, fails to meet its primary e...

Merck's endometrial cancer drug meets late-stage trial goals

Merck's endometrial cancer drug meets late-stage trial goals

6:51 18-05-2026

Merck said on Monday its experimental endometrial cancer drug met the main goals of a late-stage tri...

Why Is Regeneron Stock Sinking Monday?

Why Is Regeneron Stock Sinking Monday?

6:28 18-05-2026

Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free...

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

10:01 14-05-2026

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile ...

Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?

Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?

12:52 13-05-2026

Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could f...

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

6:45 12-05-2026

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United S...

Merck Stock Down 7% in a Month: Should Investors Hold or Exit?

Merck Stock Down 7% in a Month: Should Investors Hold or Exit?

12:21 11-05-2026

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners...

Merck Faces Gardasil Trial After $8.9 Billion Sales Peak

Merck Faces Gardasil Trial After $8.9 Billion Sales Peak

13:22 08-05-2026

Merck (MRK) is moving toward a potentially high-stakes courtroom test over Gardasil, its HPV vaccine...

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

14:05 07-05-2026

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,...

Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds

Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds

13:17 05-05-2026

Merck (NYSE:MRK | MRK Price Prediction) delivered its fourth consecutive earnings beat, but shares s...

Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk

Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk

16:56 04-05-2026

Merck stock shows a confirmed double top breakdown, signaling potential downside risk, while key mov...

Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent Loss

Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent Loss

9:35 03-05-2026

Merck retains a 'strong buy' rating, driven by proactive oncology pipeline expansion to offset KEYTR...

close

MERCK ADVANCES TREATMENT OF BLADDER AND KIDNEY CANCERS WITH NEW DATA AT 2026 ASCO GU CANCERS SYMPOSIUM

12-02-2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--MERCK ADVANCES TREATMENT OF BLADDER AND KIDNEY CANCERS ...
Více zde

KEYTRUDA® (PEMBROLIZUMAB) AND KEYTRUDA QLEX™ (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH), PLUS PACLITAXEL ± BEVACIZUMAB, APPROVED FOR CERTAIN ADULTS WITH PD-L1+ (CPS ≥1) PLATINUM-RESISTANT OVARIAN CARCINOMA AS SECOND OR THIRD LINE TREATMENT

11-02-2026
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANA...
Více zde

CALLA LILY CLINICAL CARE AND MERCK ANNOUNCE STRATEGIC COLLABORATION TO ADVANCE INTRAVAGINAL DRUG DELIVERY PLATFORM

10-02-2026
LONDON--(BUSINESS WIRE)--CALLA LILY CLINICAL CARE, A WOMEN'S HEALTH-FOCUSED MEDICAL TECHNOLOGY COMPA...
Více zde

MERCK & CO., INC., RAHWAY, N.J., USA ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS; HIGHLIGHTS PROGRESS ADVANCING BROAD, DIVERSE PIPELINE

03-02-2026
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK & CO., INC., RAHWAY, N.J., USA ANNOUNCES FOURTH-QUARTER AND FUL...
Více zde

MERCK ANNOUNCES SECOND-QUARTER 2026 DIVIDEND

27-01-2026
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK ANNOUNCES SECOND-QUARTER 2026 DIVIDEND....
Více zde

MODERNA & MERCK ANNOUNCE 5-YEAR DATA FOR INTISMERAN AUTOGENE IN COMBINATION WITH KEYTRUDA(R) (PEMBROLIZUMAB) DEMONSTRATED SUSTAINED IMPROVEMENT IN THE PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL IN PATIENTS WITH HIGH-RISK STAGE III/IV MELANOMA FOLLOWING

20-01-2026
AT A MEDIAN FIVE-YEAR PRE-PLANNED FOLLOW-UP OF THE PHASE 2B KEYNOTE-942/MRNA-4157-P201 STUDY, INTISM...
Více zde

DR. RASHA KELEJ, CEO OF MERCK FOUNDATION, NAMED ONE OF ‘100 MOST INFLUENTIAL AFRICANS 2025' ALONGSIDE PRESIDENTS OF ANGOLA, SOUTH AFRICA, AND GHANA BY NEW AFRICAN MAGAZINE, UK

07-01-2026
DUBAI, UNITED ARAB EMIRATES--(BUSINESS WIRE)-- #100MOSTINFLUENTIALAFRICANS--DR. RASHA KELEJ, CEO OF ...
Více zde

VAXXAS APPOINTS FORMER MERCK GLOBAL VACCINES PRESIDENT DAVID PEACOCK AS CEO

07-01-2026
BRISBANE, AUSTRALIA AND CAMBRIDGE, MASS., JAN. 07, 2026 (GLOBE NEWSWIRE) -- VAXXAS PTY LTD TODAY ANN...
Více zde

MERCK INITIATES PHASE 3 KANDLELIT-007 TRIAL EVALUATING CALDERASIB (MK-1084), AN INVESTIGATIONAL ORAL KRAS G12C INHIBITOR, IN COMBINATION WITH KEYTRUDA QLEX™ (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH) IN CERTAIN PATIENTS WITH ADVANCED NSCLC

07-01-2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED S...
Více zde

MERCK TO COMPLETE ACQUISITION OF CIDARA THERAPEUTICS

07-01-2026
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK TO COMPLETE ACQUISITION OF CIDARA THERAPEUTICS....
Více zde

MERCK TO HOLD FOURTH-QUARTER AND FULL-YEAR 2025 SALES AND EARNINGS CONFERENCE CALL FEB. 3

07-01-2026
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK TO HOLD FOURTH-QUARTER AND FULL-YEAR 2025 SALES AND EARNINGS CO...
Více zde

MERCK TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

05-01-2026
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFER...
Více zde

MERCK REACHES AGREEMENT WITH U.S. GOVERNMENT TO EXPAND ACCESS TO MEDICINES AND LOWER COSTS FOR AMERICANS

19-12-2025
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK REACHES AGREEMENT WITH U.S. GOVERNMENT TO EXPAND ACCESS TO MEDI...
Více zde

KEYTRUDA® (PEMBROLIZUMAB) PLUS PADCEV® (ENFORTUMAB VEDOTIN-EJFV) SIGNIFICANTLY IMPROVED EVENT-FREE SURVIVAL, OVERALL SURVIVAL AND PATHOLOGIC COMPLETE RESPONSE RATES FOR CISPLATIN-ELIGIBLE PATIENTS WITH MIBC WHEN GIVEN BEFORE AND AFTER SURGERY

17-12-2025
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE THE UNITED STATES AND CANADA,...
Více zde

MERCK RECEIVES POSITIVE EU CHMP OPINION FOR EXPANDED USE OF WINREVAIR™ (SOTATERCEPT) IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH, WHO* GROUP 1 PULMONARY HYPERTENSION)

12-12-2025
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANA...
Více zde

BENCHSCI EXTENDS ASCEND AGREEMENT WITH MERCK TO SUPPORT PRECLINICAL DISEASE BIOLOGY RESEARCH

09-12-2025
TORONTO--(BUSINESS WIRE)--BENCHSCI, A LEADING PROVIDER OF AI SOFTWARE FOR BIOPHARMA RESEARCH AND DEV...
Více zde

FORMYCON AND ZYDUS PARTNER FOR EXCLUSIVE LICENSING AND SUPPLY AGREEMENT OF FYB206, A BIOSIMILAR TO KEYTRUDA® (PEMBROLIZUMAB), IN THE U.S. AND CANADA

09-12-2025
PLANEGG-MARTINSRIED, GERMANY AND AHMEDABAD, INDIA, DEC. 09, 2025 (GLOBE NEWSWIRE) -- FORMYCON AG (FS...
Více zde

FDA CONDITIONALLY APPROVES MERCK ANIMAL HEALTH'S EXZOLT™ CATTLE-CA1 FOR THE PREVENTION AND TREATMENT OF NEW WORLD SCREWWORM (COCHLIOMYIA HOMINIVORAX) LARVAE (MYIASIS)

04-12-2025
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK ANIMAL HEALTH, KNOWN AS MSD ANIMAL HEALTH OUTSIDE OF THE UNITED...
Více zde

MERCK SHOWCASES DATA FOR ALZHEIMER'S DISEASE CANDIDATES MK-2214 AND MK-1167 AT CTAD 2025

01-12-2025
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK SHOWCASES DATA FOR ALZHEIMER'S DISEASE CANDIDATES MK-2214 AND M...
Více zde

MERCK TO PARTICIPATE IN THE CITI 2025 GLOBAL HEALTHCARE CONFERENCE

26-11-2025
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK TO PARTICIPATE IN THE CITI 2025 GLOBAL HEALTHCARE CONFERENCE....
Více zde

MERCK TO PARTICIPATE IN THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE

26-11-2025
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK TO PARTICIPATE IN THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFER...
Více zde

MERCK DATA TO BE PRESENTED AT ASH 2025 ANNUAL MEETING SHOWCASE CONTINUED ADVANCEMENTS IN HEMATOLOGY PIPELINE AND NOVEL THERAPEUTIC APPROACHES

24-11-2025
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED S...
Více zde

MERCK RECOMMENDS REJECTION OF TUTANOTA'S “MINI-TENDER” OFFER

21-11-2025
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE THE UNITED STATES AND CANADA,...
Více zde

FDA APPROVES KEYTRUDA® (PEMBROLIZUMAB) AND KEYTRUDA QLEX™ (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH), EACH WITH PADCEV® (ENFORTUMAB VEDOTIN-EJFV), AS PERIOPERATIVE TREATMENT FOR ADULTS WITH CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER

21-11-2025
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANA...
Více zde

MERCK ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PIVOTAL PHASE 3 TRIAL EVALUATING INVESTIGATIONAL, ONCE-DAILY, ORAL, TWO-DRUG, SINGLE-TABLET REGIMEN OF DORAVIRINE/ISLATRAVIR (DOR/ISL) IN TREATMENT-NAÏVE ADULTS WITH HIV-1 INFECTION

19-11-2025
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED S...
Více zde

EUROPEAN COMMISSION APPROVES SUBCUTANEOUS ADMINISTRATION OF KEYTRUDA® (PEMBROLIZUMAB) FOR ALL ADULT INDICATIONS APPROVED IN THE EUROPEAN UNION

19-11-2025
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED S...
Více zde

MERCK ANNOUNCES FIRST-QUARTER 2026 DIVIDEND

18-11-2025
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK ANNOUNCES FIRST-QUARTER 2026 DIVIDEND....
Více zde

MERCK'S WINREVAIR™ (SOTATERCEPT-CSRK) MET PRIMARY ENDPOINT IN PHASE 2 CADENCE STUDY IN ADULTS WITH COMBINED POST- AND PRECAPILLARY PULMONARY HYPERTENSION (CPCPH) DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)

18-11-2025
RAHWAY, N.J.--(BUSINESS WIRE)--MERCK'S WINREVAIR™ (SOTATERCEPT-CSRK) MET PRIMARY ENDPOINT IN PHASE...
Více zde

CIDARA THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF CIDARA THERAPEUTICS, INC. - CDTX

16-11-2025
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, ...
Více zde

MERCK TO ACQUIRE CIDARA THERAPEUTICS, INC., DIVERSIFYING ITS PORTFOLIO TO INCLUDE LATE-PHASE ANTIVIRAL AGENT

14-11-2025
RAHWAY, N.J. & SAN DIEGO, CALIF.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UN...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-03 00:00:008-KStáhnout
2025-12-04 00:00:008-KStáhnout
2025-11-05 00:00:0010-QStáhnout
2025-10-30 00:00:008-KStáhnout
2025-09-09 01:00:008-KStáhnout
2025-09-09 00:00:008-KStáhnout
2025-08-05 01:00:0010-QStáhnout
2025-08-05 00:00:0010-QStáhnout
2025-07-29 01:00:008-KStáhnout
2025-07-29 00:00:008-KStáhnout
2025-05-29 01:00:008-KStáhnout
2025-05-29 00:00:008-KStáhnout
2025-05-02 01:00:0010-QStáhnout
2025-05-02 00:00:0010-QStáhnout
2025-04-24 01:00:008-KStáhnout
2025-04-24 00:00:008-KStáhnout
2025-02-25 00:00:0010-KStáhnout
2025-02-24 23:00:0010-KStáhnout
2025-02-04 00:00:008-KStáhnout
2025-02-03 23:00:008-KStáhnout
2024-11-22 00:00:008-KStáhnout
2024-11-21 23:00:008-KStáhnout
2024-11-06 00:00:0010-QStáhnout
2024-11-05 23:00:0010-QStáhnout
2024-10-31 00:00:008-KStáhnout
2024-10-30 23:00:008-KStáhnout
2024-08-05 01:00:0010-QStáhnout
2024-08-05 00:00:0010-QStáhnout
2024-07-30 01:00:008-KStáhnout
2024-07-30 00:00:008-KStáhnout
2024-05-30 01:00:008-KStáhnout
2024-05-30 00:00:008-KStáhnout
2024-05-03 01:00:0010-QStáhnout
2024-05-03 00:00:0010-QStáhnout
2024-04-25 01:00:008-KStáhnout
2024-04-25 00:00:008-KStáhnout
2024-02-26 00:00:0010-KStáhnout
2024-02-25 23:00:0010-KStáhnout
2024-02-20 00:00:008-KStáhnout
2024-02-19 23:00:008-KStáhnout
2024-02-01 00:00:008-KStáhnout
2024-01-31 23:00:008-KStáhnout
2023-11-28 00:00:008-KStáhnout
2023-11-27 23:00:008-KStáhnout
2023-11-03 00:00:0010-QStáhnout
2023-11-02 23:00:0010-QStáhnout
2023-10-26 01:00:008-KStáhnout
2023-10-26 00:00:008-KStáhnout
2023-08-07 01:00:0010-QStáhnout
2023-08-07 00:00:0010-QStáhnout
2023-08-01 01:00:008-KStáhnout
2023-08-01 00:00:008-KStáhnout
2023-05-26 01:00:008-KStáhnout
2023-05-26 00:00:008-KStáhnout
2023-05-17 01:00:008-KStáhnout
2023-05-17 00:00:008-KStáhnout
2023-05-05 01:00:0010-QStáhnout
2023-05-05 00:00:0010-QStáhnout
2023-04-27 01:00:008-KStáhnout
2023-04-27 00:00:008-KStáhnout
2023-02-24 00:00:0010-KStáhnout
2023-02-23 23:00:0010-KStáhnout
2023-02-02 00:00:008-KStáhnout
2023-02-01 23:00:008-KStáhnout
2022-11-03 00:00:0010-QStáhnout
2022-11-02 23:00:0010-QStáhnout
2022-10-27 01:00:008-KStáhnout
2022-10-27 00:00:008-KStáhnout
2022-08-05 01:00:0010-QStáhnout
2022-08-05 00:00:0010-QStáhnout
2022-07-28 01:00:008-KStáhnout
2022-07-28 00:00:008-KStáhnout
2022-05-26 01:00:008-KStáhnout
2022-05-26 00:00:008-KStáhnout
2022-05-05 01:00:0010-QStáhnout
2022-05-05 00:00:0010-QStáhnout
2022-04-28 01:00:008-KStáhnout
2022-04-28 00:00:008-KStáhnout
2022-04-21 01:00:008-KStáhnout
2022-04-21 00:00:008-KStáhnout
2022-03-25 00:00:008-KStáhnout
2022-03-24 23:00:008-KStáhnout
2022-02-25 00:00:0010-KStáhnout
2022-02-24 23:00:0010-KStáhnout
2022-02-03 00:00:008-KStáhnout
2022-02-02 23:00:008-KStáhnout
2021-12-10 00:00:008-KStáhnout
2021-12-09 23:00:008-KStáhnout
2021-11-05 00:00:0010-QStáhnout
2021-11-04 23:00:0010-QStáhnout
2021-10-28 01:00:008-KStáhnout
2021-10-28 00:00:008-KStáhnout
2021-08-20 01:00:008-KStáhnout
2021-08-20 00:00:008-KStáhnout
2021-08-09 01:00:0010-QStáhnout
2021-08-09 00:00:0010-QStáhnout
2021-07-29 01:00:008-KStáhnout
2021-07-29 00:00:008-KStáhnout
2021-06-21 01:00:008-KStáhnout
2021-06-21 00:00:008-KStáhnout
2021-06-03 01:00:008-KStáhnout
2021-06-03 00:00:008-KStáhnout
2021-05-27 01:00:008-KStáhnout
2021-05-27 00:00:008-KStáhnout
2021-05-05 01:00:008-KStáhnout
2021-05-05 01:00:0010-QStáhnout
2021-05-05 00:00:008-KStáhnout
2021-05-05 00:00:0010-QStáhnout
2021-04-29 01:00:008-KStáhnout
2021-04-29 00:00:008-KStáhnout
2021-03-26 00:00:008-KStáhnout
2021-03-25 23:00:008-KStáhnout
2021-03-24 00:00:008-KStáhnout
2021-03-23 23:00:008-KStáhnout
2021-02-25 00:00:0010-KStáhnout
2021-02-24 23:00:0010-KStáhnout
2021-02-04 00:00:008-KStáhnout
2021-02-03 23:00:008-KStáhnout
2021-02-01 00:00:008-KStáhnout
2021-01-31 23:00:008-KStáhnout
2020-11-05 00:00:0010-QStáhnout
2020-11-04 23:00:0010-QStáhnout
2020-10-27 00:00:008-KStáhnout
2020-10-26 23:00:008-KStáhnout
2020-08-05 01:00:0010-QStáhnout
2020-08-05 00:00:0010-QStáhnout
2020-07-31 01:00:008-KStáhnout
2020-07-31 00:00:008-KStáhnout
2020-06-24 01:00:008-KStáhnout
2020-06-24 00:00:008-KStáhnout
2020-05-29 01:00:008-KStáhnout
2020-05-29 00:00:008-KStáhnout
2020-05-06 01:00:0010-QStáhnout
2020-05-06 00:00:0010-QStáhnout
2020-04-28 01:00:008-KStáhnout
2020-04-28 00:00:008-KStáhnout
2020-02-26 00:00:0010-KStáhnout
2020-02-25 23:00:0010-KStáhnout
2020-02-05 00:00:008-KStáhnout
2020-02-04 23:00:008-KStáhnout
2020-01-31 00:00:008-KStáhnout
2020-01-30 23:00:008-KStáhnout
2019-11-05 00:00:0010-QStáhnout
2019-11-04 23:00:0010-QStáhnout
2019-10-29 00:00:008-KStáhnout
2019-10-28 23:00:008-KStáhnout
2019-08-06 01:00:0010-QStáhnout
2019-08-06 00:00:0010-QStáhnout
2019-07-30 01:00:008-KStáhnout
2019-07-30 00:00:008-KStáhnout
2019-05-31 01:00:008-KStáhnout
2019-05-31 00:00:008-KStáhnout
2019-05-08 01:00:0010-QStáhnout
2019-05-08 00:00:0010-QStáhnout
2019-04-30 01:00:008-KStáhnout
2019-04-30 00:00:008-KStáhnout
2019-03-07 00:00:008-KStáhnout
2019-03-06 23:00:008-KStáhnout
2019-02-27 00:00:0010-KStáhnout
2019-02-26 23:00:0010-KStáhnout
2019-02-01 00:00:008-KStáhnout
2019-01-31 23:00:008-KStáhnout
2019-01-30 00:00:008-KStáhnout
2019-01-29 23:00:008-KStáhnout
2018-12-10 00:00:008-KStáhnout
2018-12-09 23:00:008-KStáhnout
2018-11-06 00:00:0010-QStáhnout
2018-11-05 23:00:0010-QStáhnout
2018-10-25 01:00:008-KStáhnout
2018-10-25 00:00:008-KStáhnout
2018-10-04 01:00:008-KStáhnout
2018-10-04 00:00:008-KStáhnout
2018-09-27 01:00:008-KStáhnout
2018-09-27 00:00:008-KStáhnout
2018-08-07 01:00:0010-QStáhnout
2018-08-07 00:00:0010-QStáhnout
2018-07-27 01:00:008-KStáhnout
2018-07-27 00:00:008-KStáhnout
2018-05-24 01:00:008-KStáhnout
2018-05-24 00:00:008-KStáhnout
2018-05-08 01:00:0010-QStáhnout
2018-05-08 00:00:0010-QStáhnout
2018-05-01 01:00:008-KStáhnout
2018-05-01 00:00:008-KStáhnout
2018-02-27 00:00:0010-KStáhnout
2018-02-26 23:00:0010-KStáhnout
2018-02-26 00:00:008-KStáhnout
2018-02-25 23:00:008-KStáhnout
2018-02-02 00:00:008-KStáhnout
2018-02-01 23:00:008-KStáhnout
2018-01-26 00:00:008-KStáhnout
2018-01-25 23:00:008-KStáhnout
2017-11-07 00:00:0010-QStáhnout
2017-11-06 23:00:0010-QStáhnout
2017-11-06 00:00:008-KStáhnout
2017-11-05 23:00:008-KStáhnout
2017-10-27 01:00:008-KStáhnout
2017-10-27 00:00:008-KStáhnout
2017-08-08 01:00:0010-QStáhnout
2017-08-08 00:00:0010-QStáhnout
2017-07-28 01:00:008-KStáhnout
2017-07-28 00:00:008-KStáhnout
2017-05-25 01:00:008-KStáhnout
2017-05-25 00:00:008-KStáhnout
2017-05-09 01:00:0010-QStáhnout
2017-05-09 00:00:0010-QStáhnout
2017-05-02 01:00:008-KStáhnout
2017-05-02 00:00:008-KStáhnout
2017-02-28 00:00:0010-KStáhnout
2017-02-27 23:00:0010-KStáhnout
2017-02-23 00:00:008-KStáhnout
2017-02-22 23:00:008-KStáhnout
2017-02-02 00:00:008-KStáhnout
2017-02-01 23:00:008-KStáhnout
2016-11-07 00:00:0010-QStáhnout
2016-11-06 23:00:0010-QStáhnout
2016-11-02 00:00:008-KStáhnout
2016-11-01 23:00:008-KStáhnout
2016-10-25 01:00:008-KStáhnout
2016-10-25 00:00:008-KStáhnout
2016-08-08 01:00:0010-QStáhnout
2016-08-08 00:00:0010-QStáhnout
2016-07-29 01:00:008-KStáhnout
2016-07-29 00:00:008-KStáhnout
2016-05-27 01:00:008-KStáhnout
2016-05-27 00:00:008-KStáhnout
2016-05-09 01:00:0010-QStáhnout
2016-05-09 00:00:0010-QStáhnout
2016-05-05 01:00:008-KStáhnout
2016-05-05 00:00:008-KStáhnout
2016-02-26 00:00:0010-KStáhnout
2016-02-25 23:00:0010-KStáhnout
2016-02-03 00:00:008-KStáhnout
2016-02-02 23:00:008-KStáhnout
2015-11-04 23:00:0010-QStáhnout
2015-10-26 23:00:008-KStáhnout
2015-08-06 00:00:0010-QStáhnout
2015-07-28 00:00:008-KStáhnout
2015-07-24 00:00:008-KStáhnout
preloader